Your browser doesn't support javascript.
loading
Circulating serum chemerin levels are elevated in lipodystrophy.
Miehle, Konstanze; Ebert, Thomas; Kralisch, Susan; Hoffmann, Annett; Kratzsch, Jürgen; Schlögl, Haiko; Stumvoll, Michael; Fasshauer, Mathias.
Afiliación
  • Miehle K; Department of Internal Medicine (Endocrinology and Nephrology), University of Leipzig, Leipzig, Germany.
  • Ebert T; Department of Internal Medicine (Endocrinology and Nephrology), University of Leipzig, Leipzig, Germany.
  • Kralisch S; Leipzig University Medical Center, IFB Adiposity Diseases, Leipzig, Germany.
  • Hoffmann A; Department of Internal Medicine (Endocrinology and Nephrology), University of Leipzig, Leipzig, Germany.
  • Kratzsch J; Department of Internal Medicine (Endocrinology and Nephrology), University of Leipzig, Leipzig, Germany.
  • Schlögl H; Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany.
  • Stumvoll M; Department of Internal Medicine (Endocrinology and Nephrology), University of Leipzig, Leipzig, Germany.
  • Fasshauer M; Department of Internal Medicine (Endocrinology and Nephrology), University of Leipzig, Leipzig, Germany.
Clin Endocrinol (Oxf) ; 84(6): 932-8, 2016 06.
Article en En | MEDLINE | ID: mdl-26572532
OBJECTIVE: Lipodystrophy (LD) is characterized by loss of adipose tissue, dysregulation of adipokines and severe metabolic complications. Regulation of the insulin resistance-inducing and proinflammatory adipokine chemerin has not been assessed in LD. Therefore, we determined chemerin serum levels in LD, chemerin mRNA expression in insulin-sensitive tissues of LD mice, as well as the impact of metreleptin treatment on circulating chemerin in LD patients. RESEARCH DESIGN AND METHODS: Serum chemerin, as well as clinical and biochemical parameters of glucose metabolism, lipid metabolism, and inflammation, was measured in 37 LD patients and 37 age-, gender- and body mass index-matched controls. Furthermore, chemerin mRNA expression was determined in LD mice and controls. Moreover, circulating chemerin was assessed at five different time points in 10 LD patients treated with metreleptin over 1 year. RESULTS: Median serum chemerin levels were significantly higher in 37 subjects with LD (234·3 µg/l) as compared to controls (204·0 µg/l) (P = 0·002). Multiple linear regression analysis showed that circulating chemerin was independently and positively associated with glycosylated haemoglobin A1c (HbA1c) and C-reactive protein (CRP). Chemerin mRNA expression was significantly increased 2·5-fold in visceral adipose tissue (VAT) and 5·3-fold in brown adipose tissue (BAT) of LD mice as compared to controls (P < 0·01). Circulating chemerin was not significantly altered by metreleptin treatment. CONCLUSIONS: Circulating levels of the adipokine chemerin are elevated in LD, as well as independently and positively associated with HbA1c and CRP. Increased chemerin might originate from VAT and BAT.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimiocinas / Péptidos y Proteínas de Señalización Intercelular / Lipodistrofia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimiocinas / Péptidos y Proteínas de Señalización Intercelular / Lipodistrofia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido